Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy.

Current opinion in pulmonary medicine - 1 Nov 2000

Choo-Kang L R, Zeitlin P L

Abstract excerpt

Recent advances in cellular and molecular biology have furthered the understanding of several genetic diseases, including cystic fibrosis. Mutations that cause cystic fibrosis are now understood in terms of the specific molecular consequences to the cystic fibrosis transmembrane conductance regulator (CFTR) protein expression and function. This knowledge has spawned interest in the development of therapies aimed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon, Terminator
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CFTR gene

Share to Mutation

Share to Phosphorylation

Share to Protein Folding

Share to RNA Splicing

Source

Identifiers

PMID: 11100963
DOI: 10.1097/00063198-200011000-00011

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy.PMID 11100963Read ↗

Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.Semantic proximity Read ↗

Therapies directed at the basic defect in cystic fibrosis.Semantic proximity Read ↗

Lessons from other fields of medicine, Part 2: Cystic fibrosis.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment.Semantic proximity Read ↗

Advances in the Cystic Fibrosis Drug Development PipelineSemantic proximity Read ↗

Use of protein repair therapy in the treatment of cystic fibrosis.Semantic proximity Read ↗

Targeted therapy for cystic fibrosisSemantic proximity Read ↗

Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.Semantic proximity Read ↗

Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.Semantic proximity Read ↗

New Therapies to Correct the Cystic Fibrosis Basic Defect.Semantic proximity Read ↗

New and emerging targeted therapies for cystic fibrosis.Semantic proximity Read ↗

New treatments targeting the basic defects in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.